COBENFY
Sep 30, 2024
5 Upcoming Schizophrenia Drugs Competitors for Newly Approved BMS’ KarXT (COBENFY)
After years of little progress in the field of schizophrenia drug treatment, Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics has paid off with the approval of a groundbreaking new drug. BMS’s novel medication, KarXT—now named COBENFY—received significant FDA approval on 26 September 2024 for t...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
